Protection against cisplatin ototoxicity in a Sprague-Dawley rat animal model.
Cisplatin (CDDP) is an anti-neoplastic drug extensively used in cases of head and neck cancer. Cisplatin induces numerous untoward side-effects including ototoxicity. In this study, cisplatin ototoxicity in Sprague-Dawley rat animal model has been evaluated and the oto-protection provided by the systemic administration of the antioxidant drug D-methionine has been tested. A total of 12 Sprague-Dawley rats were used: 8 were treated intra-peritoneally with D-methionine (300 mg/kg) and cisplatin (16 mg/kg, slow 30 min-infusion), 4 only with cisplatin. The hearing threshold of the animals was evaluated by electrophysiological procedures as Otoacoustic Emissions and Auditory Brainstem Responses. The effects of protection were evaluated after 72 hours. The data from the Otoacoustic Emissions (in the 4.0-12 kHz band) and Auditory Brainstem Responses recordings suggested that D-methionine can partially protect from Cisplatin ototoxicity.
Giordano
P
P
Department of Audiology, University of Ferrara, Ferrara, Italy.
Lorito
G
G
Ciorba
A
A
Martini
A
A
Hatzopoulos
S
S
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002614:Chelating Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects*; D003051:Cochlea / Q000187:drug effects* / Q000503:physiopathology*; D016057:Evoked Potentials, Auditory, Brain Stem / Q000187:drug effects; D018072:Hair Cells, Auditory, Outer / Q000187:drug effects; D008297:Male; D008715:Methionine / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
D000970:Antineoplastic Agents; D002614:Chelating Agents; D008715:Methionine; D002945:Cisplatin